The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Physiology. Heart and Circulatory Physiology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpheart.00665.2011PMID 22058153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.

  2011cited by this paper
• Cardiac Raptor Ablation Impairs Adaptive Hypertrophy, Alters Metabolic Gene Expression, and Causes Heart Failure in Mice

  2011cited by this paper
• Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

  2011influential reference
• mTOR Signalling in Health and Disease.

  2011cited by this paper
• MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

  2010cited by this paper
• mTOR: from growth signal integration to cancer, diabetes and ageing

  2010cited by this paper
• mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy.

  2010cited by this paper
• Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome

  2010cited by this paper
• Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β Signaling

  2010cited by this paper
• PTPN11 Gene Mutation and Severe Neonatal Hypertrophic Cardiomyopathy: What Is the Link?

  2009cited by this paper
• Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation

  2009cited by this paper
• Genotype–phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome

  2008cited by this paper
• MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

  2008cited by this paper
• Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome

  2008cited by this paper
• Shp2 Negatively Regulates Growth in Cardiomyocytes by Controlling Focal Adhesion Kinase/Src and mTOR Pathways

  2008cited by this paper
• Negative Inotropic Effect of Rapamycin on Isolated Human Cardiomyocytes

  2008cited by this paper
• Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft

  2008cited by this paper
• Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.

  2007cited by this paper
• Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome.

  2007cited by this paper
• PTPN11 gene mutations: linking the Gln510Glu mutation to the “LEOPARD syndrome phenotype”

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• LEOPARD syndrome: Clinical diagnosis in the first year of life

  2006influential reference
• PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects*

  2006cited by this paper
• Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

  2006cited by this paper
• A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy

  2005cited by this paper
• Noonan Syndrome Mutation Q79R in Shp2 Increases Proliferation of Valve Primordia Mesenchymal Cells via Extracellular Signal–Regulated Kinase 1/2 Signaling

  2005cited by this paper
• Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation

  2004cited by this paper
• Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation

  2004cited by this paper
• Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload

  2004cited by this paper
• Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice

  2003cited by this paper
• Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling

  2003cited by this paper
• Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart*

  2002cited by this paper
• Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice

  2002cited by this paper
• Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice

  2002cited by this paper
• PTPN11 mutations in LEOPARD syndrome

  2002cited by this paper
• Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

  2000cited by this paper
• Morphogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2.

  1999cited by this paper
• Shp-2 tyrosine phosphatase: signaling one cell or many.

  1999cited by this paper
• SHP-2, SH2-containing protein tyrosine phosphatase-2.

  1998cited by this paper
• Insulin Signaling in Mice Expressing Reduced Levels of Syp*

  1996cited by this paper
• Transgenic analysis of the thyroid-responsive elements in the alpha-cardiac myosin heavy chain gene promoter.

  1993cited by this paper
• In vivo analysis of the murine beta-myosin heavy chain gene promoter.

  1993cited by this paper
• Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart.

  1991cited by this paper
• Multiple Lentigenes Syndrome: Complex Comprising Multiple Lentigenes, Electrocardiographic Conduction Abnormalities, Ocular Hypertelorism, Pulmonary Stenosis, Abnormalities of Genitalia, Retardation of Growth, Sensorineural Deafness, and Autosomal Dominant Hereditary Pattern

  1969cited by this paper
• Multiple lentigenes syndrome.

  1969cited by this paper

• SHP2 happens, just sail with it: the role of the protein tyrosine phosphatase SHP2 in autoimmune and autoinflammatory diseases

  2025cites this paper
• The mTOR Signaling Pathway: Key Regulator and Therapeutic Target for Heart Disease

  2025cites this paper
• Cardiovascular aspects of Noonan syndrome and related disorders

  2025cites this paper
• Integrated Multi-omics Analysis of Hub Genes and miRNA Interactions in Hypertrophic Cardiomyopathy

  2025cites this paper
• [Hypertrophy of the lumbosacral nerve roots in Noonan syndrome with multiple lentigines: a case report].

  2025cites this paper
• Adaptor protein Src-homology 2 domain containing E (SH2E) deficiency induces heart defect in zebrafish

  2024cites this paper
• Computational study on the binding mechanism of allosteric drug TNO155 inhibiting SHP2E76A

  2024cites this paper
• Cardiac Phenotype and Gene Mutations in RASopathies

  2024cites this paper
• Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics

  2024cites this paper
• Setting sail: Maneuvering SHP2 activity and its effects in cancer.

  2023cites this paper
• Induced pluripotent stem cells for modeling Noonan, Noonan Syndrome with Multiple Lentigines, and Costello Syndromes

  2022cites this paper
• Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2

  2022cites this paper
• Integrated identification of key immune related genes and patterns of immune infiltration in calcified aortic valvular disease: A network based meta-analysis

  2022cites this paper
• A comprehensive review of SHP2 and its role in cancer

  2022cites this paper
• A pan-cancer analysis confirms PTPN11’s potential as a prognostic and immunological biomarker

  2022cites this paper
• Friend or foe? Unraveling the complex roles of protein tyrosine phosphatases in cardiac disease and development.

  2022cites this paper
• An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies

  2022cites this paper
• Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.

  2022cites this paper
• Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome

  2021cites this paper
• Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms

  2021cites this paper
• Multi-target pharmacological mechanisms of Salvia miltiorrhiza against oral submucous fibrosis: A network pharmacology approach.

  2021cites this paper
• Shared Molecular Mechanisms of Hypertrophic Cardiomyopathy and Its Clinical Presentations: Automated Molecular Mechanisms Extraction Approach

  2021cites this paper
• Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.

  2020cites this paper
• Genotype–phenotype association by echocardiography offers incremental value in patients with Noonan Syndrome with Multiple Lentigines

  2020cites this paper
• mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?

  2019cites this paper
• Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy.

  2019cites this paper
• An update on the central nervous system manifestations of tuberous sclerosis complex

  2019cites this paper
• Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations

  2019cites this paper
• Cardiac transplantation in children with Noonan syndrome

  2019cites this paper
• The role of tyrosine phosphatase Shp2 in spermatogonial differentiation and spermatocyte meiosis

  2019cites this paper
• Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy.

  2019cites this paper
• Etude des anomalies du métabolisme énergétique associées au syndrome de Noonan

  2019cites this paper
• Shp2 in myocytes is essential for cardiovascular and neointima development.

  2019cites this paper
• RAS signalling in energy metabolism and rare human diseases.

  2018cites this paper
• Protein tyrosine phosphatases in cardiac physiology and pathophysiology

  2018cites this paper
• The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.

  2018influential citation
• miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun

  2018cites this paper
• Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique

  2018cites this paper
• Decoding disease-causing mechanisms of missense mutations from supramolecular structures

  2017cites this paper
• Modeling RASopathies with Genetically Modified Mouse Models.

  2017cites this paper
• Analyzing pathogenic MEK variants in zebrafish

  2017cites this paper
• ERK Signaling

  2017cites this paper
• Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.

  2017cites this paper
• CEACAM1-Mediated Inhibition of Virus Production

  2016cites this paper
• SHP2 : une cible potentielle d’intérêt dans l’obésité et ses complications métaboliques ?

  2016cites this paper
• Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.

  2016influential citation
• Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome.

  2016cites this paper
• Bone Marrow Mesenchymal Stem Cells (BM-MSCs) Improve Heart Function in Swine Myocardial Infarction Model through Paracrine Effects

  2016cites this paper
• mTOR, cardiomyocytes and inflammation in cardiac hypertrophy.

  2016cites this paper
• Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.

  2016cites this paper
• Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

  2015cites this paper
• RASopathies: unraveling mechanisms with animal models

  2015cites this paper
• Pharmacological targeting of AKAP-directed compartmentalized cAMP signalling.

  2015cites this paper
• The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.

  2015cites this paper
• SHP2 sails from physiology to pathology.

  2015cites this paper
• Noonan Syndrome with Multiple Lentigines: Insights into Hypertrophy and Hypercontractility

  2015influential citation
• Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: Palliative treatment with a rapamycin analog

  2015influential citation
• DEV106310 1961..1970

  2014cites this paper
• LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity

  2014influential citation
• SHP-2 deletion in postmigratory neural crest cells results in impaired cardiac sympathetic innervation

  2014cites this paper
• N-of-1 genomic medicine for the rare pediatric genetic diseases

  2014cites this paper
• The Role of FGF Signaling in the Regulation of Adult Murine Cardiomyocyte Contractility and Pathologic Hypertrophy

  2014cites this paper
• Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

  2014cites this paper
• Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP) - pure coincidence?

  2014cites this paper
• MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1

  2014cites this paper
• Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish

  2014cites this paper
• MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis

  2014cites this paper
• Noonan and LEOPARD syndrome in zebrafish : molecular mechanisms and cardiac development

  2014cites this paper
• DEV106310 1..10

  2014cites this paper
• The Molecular Biology of Chronic Heart Failure

  2013cites this paper
• New Approaches to Prevent LEOPARD Syndrome-associated Cardiac Hypertrophy by Specifically Targeting Shp2-dependent Signaling*

  2013cites this paper
• Role of the SHP2 Protein Tyrosine Phosphatase in Cardiac Metabolism

  2013cites this paper
• Cardiac‐specific Hexokinase 2 Overexpression Attenuates Hypertrophy by Increasing Pentose Phosphate Pathway Flux

  2013cites this paper
• ROCKs cause SHP-wrecks and broken hearts

  2012cites this paper
• PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

  2011influential citation
• CEACAM 1-Mediated Inhib ition of Virus Production Graphical Abstract Highlights

  year unknowncites this paper